Treatment Strategy Trials

African DART Study Confirms Risk of Strategic Treatment Interruption   - 8/25/06

Four Drugs No Better than Three for First-line Efavirenz-Based Therapy  - 8/22/06

A 3-drug Class HAART Strategy Is Not Superior to a 2-drug Class Strategy for Immunologic or Clinical Outcomes  - 8/15/066